BridgeBio Pharma, Inc. Payments for Restructuring
BridgeBio Pharma, Inc. (BBIO) reported Payments for Restructuring of $14.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-02-24
- BridgeBio Pharma, Inc. payments for restructuring for the quarter ending 2025-12-31 was $6.52M, a 27.00% increase year-over-year.
- BridgeBio Pharma, Inc. payments for restructuring for the quarter ending 2025-09-30 was $5.31M, a 3.73% increase year-over-year.
- BridgeBio Pharma, Inc. payments for restructuring for the quarter ending 2025-06-30 was $1.28M, a 41.34% decline year-over-year.
- BridgeBio Pharma, Inc. payments for restructuring for the quarter ending 2025-03-31 was $1.36M, a 46.15% increase year-over-year.
- BridgeBio Pharma, Inc. payments for restructuring for fiscal 2025 was $14.48M, a 8.25% increase from fiscal 2024.
- BridgeBio Pharma, Inc. payments for restructuring for fiscal 2024 was $13.37M, a 9.00% decline from fiscal 2023.
- BridgeBio Pharma, Inc. payments for restructuring for fiscal 2023 was $14.70M, a 41.75% decline from fiscal 2022.
- BridgeBio Pharma, Inc. payments for restructuring for fiscal 2022 was $25.23M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.83M derived: sum of 2 quarters · filed 2026-02-24 | $13.11M derived: sum of 3 quarters · filed 2026-02-24 | $14.48M 10-K · filed 2026-02-24 |
| 2025-09-30 | $5.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $6.59M derived: sum of 2 quarters · filed 2025-10-29 | $7.96M 10-Q · filed 2025-10-29 | $13.09M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.65M 10-Q · filed 2025-08-05 | $7.78M derived: sum of 3 quarters · filed 2026-02-24 | $12.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $1.36M 10-Q · filed 2025-04-29 | $6.50M derived: sum of 2 quarters · filed 2026-02-24 | $11.62M derived: sum of 3 quarters · filed 2026-02-24 | $13.80M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.25M derived: sum of 2 quarters · filed 2026-02-24 | $12.44M derived: sum of 3 quarters · filed 2026-02-24 | $13.37M 10-K · filed 2026-02-24 |
| 2024-09-30 | $5.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $7.31M derived: sum of 2 quarters · filed 2025-10-29 | $8.24M 10-Q · filed 2025-10-29 | $9.09M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.12M 10-Q · filed 2025-08-05 | $3.97M derived: sum of 3 quarters · filed 2026-02-24 | $6.29M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $934.00K 10-Q · filed 2025-04-29 | $1.78M derived: sum of 2 quarters · filed 2026-02-24 | $4.11M derived: sum of 3 quarters · filed 2026-02-24 | $6.73M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $846.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.17M derived: sum of 2 quarters · filed 2026-02-24 | $5.79M derived: sum of 3 quarters · filed 2026-02-24 | $14.70M 10-K · filed 2026-02-24 |
| 2023-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.95M derived: sum of 2 quarters · filed 2024-11-12 | $13.85M 10-Q · filed 2024-11-12 | $21.47M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $11.53M 10-Q · filed 2024-08-01 | $19.14M derived: sum of 3 quarters · filed 2025-02-20 | $28.56M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $8.90M 10-Q · filed 2024-05-02 | $16.52M derived: sum of 2 quarters · filed 2025-02-20 | $25.94M derived: sum of 3 quarters · filed 2025-02-20 | $30.27M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $17.04M derived: sum of 2 quarters · filed 2025-02-20 | $21.36M derived: sum of 3 quarters · filed 2025-02-20 | $25.23M 10-K · filed 2025-02-20 |
| 2022-09-30 | $9.42M 10-Q · filed 2022-11-03 | $13.75M derived: sum of 2 quarters · filed 2022-11-03 | $17.62M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $4.33M 10-Q · filed 2022-08-04 | $8.20M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $3.87M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |